Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These companies are often building limitations to coverage, such as steep price requirements and